nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—Scab—Fluorouracil—colon cancer	0.0315	0.0315	CcSEcCtD
Deferoxamine—Urine color abnormal—Capecitabine—colon cancer	0.0297	0.0297	CcSEcCtD
Deferoxamine—Lung infiltration—Irinotecan—colon cancer	0.0223	0.0223	CcSEcCtD
Deferoxamine—Scab—Capecitabine—colon cancer	0.022	0.022	CcSEcCtD
Deferoxamine—Chromaturia—Capecitabine—colon cancer	0.0196	0.0196	CcSEcCtD
Deferoxamine—Blindness—Vincristine—colon cancer	0.0194	0.0194	CcSEcCtD
Deferoxamine—Local reaction—Fluorouracil—colon cancer	0.0181	0.0181	CcSEcCtD
Deferoxamine—Serum creatinine increased—Irinotecan—colon cancer	0.017	0.017	CcSEcCtD
Deferoxamine—Respiratory distress—Vincristine—colon cancer	0.0169	0.0169	CcSEcCtD
Deferoxamine—Retinal disorder—Methotrexate—colon cancer	0.0146	0.0146	CcSEcCtD
Deferoxamine—Visual acuity reduced—Capecitabine—colon cancer	0.0118	0.0118	CcSEcCtD
Deferoxamine—Serum creatinine increased—Capecitabine—colon cancer	0.0114	0.0114	CcSEcCtD
Deferoxamine—Bone pain—Vincristine—colon cancer	0.0112	0.0112	CcSEcCtD
Deferoxamine—Lung infiltration—Methotrexate—colon cancer	0.0111	0.0111	CcSEcCtD
Deferoxamine—Respiratory distress—Capecitabine—colon cancer	0.011	0.011	CcSEcCtD
Deferoxamine—Aphasia—Capecitabine—colon cancer	0.0108	0.0108	CcSEcCtD
Deferoxamine—Neuropathy—Vincristine—colon cancer	0.0101	0.0101	CcSEcCtD
Deferoxamine—Injection site pain—Capecitabine—colon cancer	0.00857	0.00857	CcSEcCtD
Deferoxamine—Swelling—Fluorouracil—colon cancer	0.00824	0.00824	CcSEcCtD
Deferoxamine—Renal failure acute—Irinotecan—colon cancer	0.00822	0.00822	CcSEcCtD
Deferoxamine—Aphasia—Methotrexate—colon cancer	0.00803	0.00803	CcSEcCtD
Deferoxamine—Visual disturbance—Irinotecan—colon cancer	0.008	0.008	CcSEcCtD
Deferoxamine—Renal impairment—Irinotecan—colon cancer	0.00797	0.00797	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Irinotecan—colon cancer	0.00784	0.00784	CcSEcCtD
Deferoxamine—Liver disorder—Methotrexate—colon cancer	0.00764	0.00764	CcSEcCtD
Deferoxamine—Cyanosis—Methotrexate—colon cancer	0.00736	0.00736	CcSEcCtD
Deferoxamine—Cataract—Capecitabine—colon cancer	0.00735	0.00735	CcSEcCtD
Deferoxamine—Bone pain—Capecitabine—colon cancer	0.0073	0.0073	CcSEcCtD
Deferoxamine—Blood creatinine increased—Irinotecan—colon cancer	0.00711	0.00711	CcSEcCtD
Deferoxamine—Injection site reaction—Capecitabine—colon cancer	0.00695	0.00695	CcSEcCtD
Deferoxamine—Neuropathy—Capecitabine—colon cancer	0.00657	0.00657	CcSEcCtD
Deferoxamine—Dysuria—Vincristine—colon cancer	0.00629	0.00629	CcSEcCtD
Deferoxamine—Eosinophilia—Fluorouracil—colon cancer	0.00622	0.00622	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Vincristine—colon cancer	0.00588	0.00588	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Capecitabine—colon cancer	0.00581	0.00581	CcSEcCtD
Deferoxamine—Bone disorder—Methotrexate—colon cancer	0.00576	0.00576	CcSEcCtD
Deferoxamine—Swelling—Capecitabine—colon cancer	0.00575	0.00575	CcSEcCtD
Deferoxamine—Renal failure—Irinotecan—colon cancer	0.00575	0.00575	CcSEcCtD
Deferoxamine—Infestation—Fluorouracil—colon cancer	0.0056	0.0056	CcSEcCtD
Deferoxamine—Infestation NOS—Fluorouracil—colon cancer	0.0056	0.0056	CcSEcCtD
Deferoxamine—Renal failure acute—Capecitabine—colon cancer	0.0055	0.0055	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Fluorouracil—colon cancer	0.00549	0.00549	CcSEcCtD
Deferoxamine—Hallucination—Vincristine—colon cancer	0.00536	0.00536	CcSEcCtD
Deferoxamine—Bradycardia—Irinotecan—colon cancer	0.00534	0.00534	CcSEcCtD
Deferoxamine—Renal impairment—Capecitabine—colon cancer	0.00533	0.00533	CcSEcCtD
Deferoxamine—Urinary tract disorder—Vincristine—colon cancer	0.00532	0.00532	CcSEcCtD
Deferoxamine—Connective tissue disorder—Vincristine—colon cancer	0.0053	0.0053	CcSEcCtD
Deferoxamine—Urethral disorder—Vincristine—colon cancer	0.00528	0.00528	CcSEcCtD
Deferoxamine—Connective tissue disorder—Irinotecan—colon cancer	0.00516	0.00516	CcSEcCtD
Deferoxamine—Visual impairment—Irinotecan—colon cancer	0.00506	0.00506	CcSEcCtD
Deferoxamine—Angiopathy—Vincristine—colon cancer	0.00489	0.00489	CcSEcCtD
Deferoxamine—Mediastinal disorder—Vincristine—colon cancer	0.00486	0.00486	CcSEcCtD
Deferoxamine—Angiopathy—Irinotecan—colon cancer	0.00476	0.00476	CcSEcCtD
Deferoxamine—Blood creatinine increased—Capecitabine—colon cancer	0.00476	0.00476	CcSEcCtD
Deferoxamine—Immune system disorder—Irinotecan—colon cancer	0.00474	0.00474	CcSEcCtD
Deferoxamine—Mediastinal disorder—Irinotecan—colon cancer	0.00473	0.00473	CcSEcCtD
Deferoxamine—Arrhythmia—Irinotecan—colon cancer	0.00469	0.00469	CcSEcCtD
Deferoxamine—Arrhythmia—Fluorouracil—colon cancer	0.00449	0.00449	CcSEcCtD
Deferoxamine—Muscle spasms—Irinotecan—colon cancer	0.00439	0.00439	CcSEcCtD
Deferoxamine—Asthma—Capecitabine—colon cancer	0.00439	0.00439	CcSEcCtD
Deferoxamine—Erythema—Fluorouracil—colon cancer	0.00438	0.00438	CcSEcCtD
Deferoxamine—Abdominal discomfort—Capecitabine—colon cancer	0.00421	0.00421	CcSEcCtD
Deferoxamine—Leukopenia—Vincristine—colon cancer	0.0042	0.0042	CcSEcCtD
Deferoxamine—Vision blurred—Fluorouracil—colon cancer	0.00412	0.00412	CcSEcCtD
Deferoxamine—Dysuria—Capecitabine—colon cancer	0.0041	0.0041	CcSEcCtD
Deferoxamine—Renal failure acute—Methotrexate—colon cancer	0.00409	0.00409	CcSEcCtD
Deferoxamine—Leukopenia—Irinotecan—colon cancer	0.00409	0.00409	CcSEcCtD
Deferoxamine—Convulsion—Vincristine—colon cancer	0.00406	0.00406	CcSEcCtD
Deferoxamine—Myalgia—Vincristine—colon cancer	0.00399	0.00399	CcSEcCtD
Deferoxamine—Visual disturbance—Methotrexate—colon cancer	0.00399	0.00399	CcSEcCtD
Deferoxamine—Leukopenia—Fluorouracil—colon cancer	0.00392	0.00392	CcSEcCtD
Deferoxamine—Infestation NOS—Capecitabine—colon cancer	0.00391	0.00391	CcSEcCtD
Deferoxamine—Infestation—Capecitabine—colon cancer	0.00391	0.00391	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Methotrexate—colon cancer	0.0039	0.0039	CcSEcCtD
Deferoxamine—Renal failure—Capecitabine—colon cancer	0.00385	0.00385	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Capecitabine—colon cancer	0.00384	0.00384	CcSEcCtD
Deferoxamine—Anaphylactic shock—Vincristine—colon cancer	0.00383	0.00383	CcSEcCtD
Deferoxamine—Oedema—Vincristine—colon cancer	0.00383	0.00383	CcSEcCtD
Deferoxamine—Infection—Vincristine—colon cancer	0.0038	0.0038	CcSEcCtD
Deferoxamine—Convulsion—Fluorouracil—colon cancer	0.00379	0.00379	CcSEcCtD
Deferoxamine—Nervous system disorder—Vincristine—colon cancer	0.00375	0.00375	CcSEcCtD
Deferoxamine—Thrombocytopenia—Vincristine—colon cancer	0.00375	0.00375	CcSEcCtD
Deferoxamine—Oedema—Irinotecan—colon cancer	0.00373	0.00373	CcSEcCtD
Deferoxamine—Anaphylactic shock—Irinotecan—colon cancer	0.00373	0.00373	CcSEcCtD
Deferoxamine—Myalgia—Fluorouracil—colon cancer	0.00372	0.00372	CcSEcCtD
Deferoxamine—Infection—Irinotecan—colon cancer	0.0037	0.0037	CcSEcCtD
Deferoxamine—Shock—Irinotecan—colon cancer	0.00367	0.00367	CcSEcCtD
Deferoxamine—Nervous system disorder—Irinotecan—colon cancer	0.00366	0.00366	CcSEcCtD
Deferoxamine—Thrombocytopenia—Irinotecan—colon cancer	0.00365	0.00365	CcSEcCtD
Deferoxamine—Hypotension—Vincristine—colon cancer	0.00358	0.00358	CcSEcCtD
Deferoxamine—Bradycardia—Capecitabine—colon cancer	0.00358	0.00358	CcSEcCtD
Deferoxamine—Oedema—Fluorouracil—colon cancer	0.00357	0.00357	CcSEcCtD
Deferoxamine—Anaphylactic shock—Fluorouracil—colon cancer	0.00357	0.00357	CcSEcCtD
Deferoxamine—Infection—Fluorouracil—colon cancer	0.00355	0.00355	CcSEcCtD
Deferoxamine—Nervous system disorder—Fluorouracil—colon cancer	0.0035	0.0035	CcSEcCtD
Deferoxamine—Thrombocytopenia—Fluorouracil—colon cancer	0.0035	0.0035	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Vincristine—colon cancer	0.00349	0.00349	CcSEcCtD
Deferoxamine—Tachycardia—Fluorouracil—colon cancer	0.00348	0.00348	CcSEcCtD
Deferoxamine—Hypotension—Irinotecan—colon cancer	0.00348	0.00348	CcSEcCtD
Deferoxamine—Urinary tract disorder—Capecitabine—colon cancer	0.00347	0.00347	CcSEcCtD
Deferoxamine—Connective tissue disorder—Capecitabine—colon cancer	0.00345	0.00345	CcSEcCtD
Deferoxamine—Urethral disorder—Capecitabine—colon cancer	0.00344	0.00344	CcSEcCtD
Deferoxamine—Paraesthesia—Vincristine—colon cancer	0.00344	0.00344	CcSEcCtD
Deferoxamine—Visual impairment—Capecitabine—colon cancer	0.00338	0.00338	CcSEcCtD
Deferoxamine—Paraesthesia—Irinotecan—colon cancer	0.00335	0.00335	CcSEcCtD
Deferoxamine—Hypotension—Fluorouracil—colon cancer	0.00334	0.00334	CcSEcCtD
Deferoxamine—Dyspnoea—Irinotecan—colon cancer	0.00332	0.00332	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Vincristine—colon cancer	0.00331	0.00331	CcSEcCtD
Deferoxamine—Eye disorder—Capecitabine—colon cancer	0.00328	0.00328	CcSEcCtD
Deferoxamine—Tinnitus—Capecitabine—colon cancer	0.00327	0.00327	CcSEcCtD
Deferoxamine—Pain—Vincristine—colon cancer	0.00327	0.00327	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—colon cancer	0.00327	0.00327	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00325	0.00325	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—colon cancer	0.00323	0.00323	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Irinotecan—colon cancer	0.00322	0.00322	CcSEcCtD
Deferoxamine—Paraesthesia—Fluorouracil—colon cancer	0.00321	0.00321	CcSEcCtD
Deferoxamine—Pain—Irinotecan—colon cancer	0.00319	0.00319	CcSEcCtD
Deferoxamine—Angiopathy—Capecitabine—colon cancer	0.00319	0.00319	CcSEcCtD
Deferoxamine—Dyspnoea—Fluorouracil—colon cancer	0.00318	0.00318	CcSEcCtD
Deferoxamine—Immune system disorder—Capecitabine—colon cancer	0.00317	0.00317	CcSEcCtD
Deferoxamine—Mediastinal disorder—Capecitabine—colon cancer	0.00317	0.00317	CcSEcCtD
Deferoxamine—Arrhythmia—Capecitabine—colon cancer	0.00314	0.00314	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—colon cancer	0.00313	0.00313	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Vincristine—colon cancer	0.00313	0.00313	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00308	0.00308	CcSEcCtD
Deferoxamine—Erythema—Capecitabine—colon cancer	0.00306	0.00306	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—colon cancer	0.00305	0.00305	CcSEcCtD
Deferoxamine—Pain—Fluorouracil—colon cancer	0.00305	0.00305	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Irinotecan—colon cancer	0.00305	0.00305	CcSEcCtD
Deferoxamine—Body temperature increased—Vincristine—colon cancer	0.00303	0.00303	CcSEcCtD
Deferoxamine—Abdominal pain—Vincristine—colon cancer	0.00303	0.00303	CcSEcCtD
Deferoxamine—Abdominal pain—Irinotecan—colon cancer	0.00295	0.00295	CcSEcCtD
Deferoxamine—Body temperature increased—Irinotecan—colon cancer	0.00295	0.00295	CcSEcCtD
Deferoxamine—Muscle spasms—Capecitabine—colon cancer	0.00294	0.00294	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—colon cancer	0.00291	0.00291	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—colon cancer	0.00291	0.00291	CcSEcCtD
Deferoxamine—Vision blurred—Capecitabine—colon cancer	0.00288	0.00288	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—colon cancer	0.00286	0.00286	CcSEcCtD
Deferoxamine—Urticaria—Fluorouracil—colon cancer	0.00284	0.00284	CcSEcCtD
Deferoxamine—Body temperature increased—Fluorouracil—colon cancer	0.00282	0.00282	CcSEcCtD
Deferoxamine—Hypersensitivity—Vincristine—colon cancer	0.00282	0.00282	CcSEcCtD
Deferoxamine—Hypersensitivity—Irinotecan—colon cancer	0.00275	0.00275	CcSEcCtD
Deferoxamine—Leukopenia—Capecitabine—colon cancer	0.00274	0.00274	CcSEcCtD
Deferoxamine—Hypersensitivity—Fluorouracil—colon cancer	0.00263	0.00263	CcSEcCtD
Deferoxamine—Diarrhoea—Vincristine—colon cancer	0.00262	0.00262	CcSEcCtD
Deferoxamine—Myalgia—Capecitabine—colon cancer	0.0026	0.0026	CcSEcCtD
Deferoxamine—Arthralgia—Capecitabine—colon cancer	0.0026	0.0026	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00258	0.00258	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—colon cancer	0.00258	0.00258	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—colon cancer	0.00256	0.00256	CcSEcCtD
Deferoxamine—Diarrhoea—Irinotecan—colon cancer	0.00255	0.00255	CcSEcCtD
Deferoxamine—Dizziness—Vincristine—colon cancer	0.00253	0.00253	CcSEcCtD
Deferoxamine—Pruritus—Fluorouracil—colon cancer	0.00253	0.00253	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—colon cancer	0.00252	0.00252	CcSEcCtD
Deferoxamine—Oedema—Capecitabine—colon cancer	0.0025	0.0025	CcSEcCtD
Deferoxamine—Infection—Capecitabine—colon cancer	0.00248	0.00248	CcSEcCtD
Deferoxamine—Dizziness—Irinotecan—colon cancer	0.00247	0.00247	CcSEcCtD
Deferoxamine—Shock—Capecitabine—colon cancer	0.00245	0.00245	CcSEcCtD
Deferoxamine—Nervous system disorder—Capecitabine—colon cancer	0.00245	0.00245	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—colon cancer	0.00244	0.00244	CcSEcCtD
Deferoxamine—Diarrhoea—Fluorouracil—colon cancer	0.00244	0.00244	CcSEcCtD
Deferoxamine—Thrombocytopenia—Capecitabine—colon cancer	0.00244	0.00244	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—colon cancer	0.00244	0.00244	CcSEcCtD
Deferoxamine—Tachycardia—Capecitabine—colon cancer	0.00244	0.00244	CcSEcCtD
Deferoxamine—Vomiting—Vincristine—colon cancer	0.00243	0.00243	CcSEcCtD
Deferoxamine—Skin disorder—Capecitabine—colon cancer	0.00242	0.00242	CcSEcCtD
Deferoxamine—Headache—Vincristine—colon cancer	0.0024	0.0024	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—colon cancer	0.00237	0.00237	CcSEcCtD
Deferoxamine—Vomiting—Irinotecan—colon cancer	0.00237	0.00237	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—colon cancer	0.00236	0.00236	CcSEcCtD
Deferoxamine—Dizziness—Fluorouracil—colon cancer	0.00236	0.00236	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—colon cancer	0.00236	0.00236	CcSEcCtD
Deferoxamine—Headache—Irinotecan—colon cancer	0.00234	0.00234	CcSEcCtD
Deferoxamine—Hypotension—Capecitabine—colon cancer	0.00233	0.00233	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—colon cancer	0.00228	0.00228	CcSEcCtD
Deferoxamine—Nausea—Vincristine—colon cancer	0.00227	0.00227	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00227	0.00227	CcSEcCtD
Deferoxamine—Vomiting—Fluorouracil—colon cancer	0.00227	0.00227	CcSEcCtD
Deferoxamine—Paraesthesia—Capecitabine—colon cancer	0.00224	0.00224	CcSEcCtD
Deferoxamine—Headache—Fluorouracil—colon cancer	0.00224	0.00224	CcSEcCtD
Deferoxamine—Dyspnoea—Capecitabine—colon cancer	0.00222	0.00222	CcSEcCtD
Deferoxamine—Nausea—Irinotecan—colon cancer	0.00221	0.00221	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Capecitabine—colon cancer	0.00215	0.00215	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—colon cancer	0.00214	0.00214	CcSEcCtD
Deferoxamine—Pain—Capecitabine—colon cancer	0.00213	0.00213	CcSEcCtD
Deferoxamine—Nausea—Fluorouracil—colon cancer	0.00212	0.00212	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Capecitabine—colon cancer	0.00204	0.00204	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—colon cancer	0.00204	0.00204	CcSEcCtD
Deferoxamine—Urticaria—Capecitabine—colon cancer	0.00198	0.00198	CcSEcCtD
Deferoxamine—Abdominal pain—Capecitabine—colon cancer	0.00197	0.00197	CcSEcCtD
Deferoxamine—Body temperature increased—Capecitabine—colon cancer	0.00197	0.00197	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—colon cancer	0.00197	0.00197	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—colon cancer	0.00194	0.00194	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—colon cancer	0.00194	0.00194	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00192	0.00192	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—colon cancer	0.00186	0.00186	CcSEcCtD
Deferoxamine—Infection—Methotrexate—colon cancer	0.00185	0.00185	CcSEcCtD
Deferoxamine—Hypersensitivity—Capecitabine—colon cancer	0.00184	0.00184	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—colon cancer	0.00182	0.00182	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—colon cancer	0.00182	0.00182	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—colon cancer	0.0018	0.0018	CcSEcCtD
Deferoxamine—Pruritus—Capecitabine—colon cancer	0.00177	0.00177	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—colon cancer	0.00174	0.00174	CcSEcCtD
Deferoxamine—Diarrhoea—Capecitabine—colon cancer	0.00171	0.00171	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00169	0.00169	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—colon cancer	0.00167	0.00167	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—colon cancer	0.00166	0.00166	CcSEcCtD
Deferoxamine—Dizziness—Capecitabine—colon cancer	0.00165	0.00165	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—colon cancer	0.0016	0.0016	CcSEcCtD
Deferoxamine—Pain—Methotrexate—colon cancer	0.00159	0.00159	CcSEcCtD
Deferoxamine—Vomiting—Capecitabine—colon cancer	0.00159	0.00159	CcSEcCtD
Deferoxamine—Headache—Capecitabine—colon cancer	0.00156	0.00156	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—colon cancer	0.00152	0.00152	CcSEcCtD
Deferoxamine—Nausea—Capecitabine—colon cancer	0.00148	0.00148	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—colon cancer	0.00148	0.00148	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—colon cancer	0.00147	0.00147	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—colon cancer	0.00147	0.00147	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—colon cancer	0.00137	0.00137	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—colon cancer	0.00131	0.00131	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—colon cancer	0.00127	0.00127	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—colon cancer	0.00123	0.00123	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—colon cancer	0.00118	0.00118	CcSEcCtD
Deferoxamine—Headache—Methotrexate—colon cancer	0.00116	0.00116	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—colon cancer	0.0011	0.0011	CcSEcCtD
